Research advances in the pathogenesis of multiple organ dysfunction syndrome in patients with liver cirrhosis and related treatment regimens

Gu TianYi; Lu LunGen

doi:10.3969/j.issn.1001-5256.2017.06.032

Issue 6

Jun. 2017

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(6): 1165-1168

PDF( 1444 KB)

Research advances in the pathogenesis of multiple organ dysfunction syndrome in patients with liver cirrhosis and related treatment regimens

DOI: 10.3969/j.issn.1001-5256.2017.06.032

Department of Gastroenterology, The First People's Hospital Affiliated to Shanghai Jiao Tong University

Received Date: 2016-12-26
Published Date: 2017-06-20

Abstract

Abstract

Recent studies have shown that complications of cirrhotic portal hypertension often involve multiple organs, which is called multiple organ dysfunction syndrome by some scholars. When multiple organ failure occurs, there is a significant increase in patients' short-term death rate, and death rate is associated with the number of organs involved. This article briefly describes the physiopathologic mechanisms of portal hypertension and visceral vasodilation and summarizes the pathological changes of vital organs including the heart, lung, kidney, brain, and liver and related pathogenesis. At present, liver transplantation remains the most effective therapy, but it still has some shortcomings. It is pointed out that further studies are needed to investigate the mechanisms of action of each link in disease development, and more targets are needed in the future to prevent and treat multiple organ dysfunction syndrome in patients with liver cirrhosis.
- liver cirrhosis,
- hypertension, portal,
- multiple organ failure,
- review

FullText(HTML)

References(41)

References

[1]GARCIA-TSAO G, BOSCH J.Management of varices and variceal hemorrhage in cirrhosis[J].N Engl J Med, 2010, 362 (9) :823-832.

[2]MEHTA G, GUSTOT T, MOOKERJEE RP, et al.Inflammation and portal hypertension-the undiscovered country[J].J Hepatol, 2014, 61 (1) :155-163.

[3]SCHWABE RF, SEKI E, BRENNER DA.Toll-like receptor signaling in the liver[J].Gastroenterol, 2006, 130 (6) :1886-1900.

[4]TAURA K, de MINICIS S, SEKI E, et al.Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis[J].Gastroenterol, 2008, 135 (5) :1729-1738.

[5]STEIB CJ, HARTMANN AC, v HESLER C, et al.Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis[J].Lab Invest, 2010, 90 (7) :1024-1032.

[6]YOKOMORI H, ODA M, YOSHIMURA K, et al.Overexpression of apelin receptor (APJ/AGTRL1) on hepatic stellate cells and sinusoidal angiogenesis in human cirrhotic liver[J].J Gastroenterol, 2011, 46 (2) :222-231.

[7]MEJIAS M, COCH L, BERZIGOTTI A, et al.Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats[J].Gut, 2015, 64 (4) :657-666.

[8]HU LS, GEORGE J, WANG JH, et al.Current concepts on the role of nitric oxide in portal hypertension[J].World J Gastroenterol, 2013, 19 (11) :1707-1717.

[9]IWAKIRI Y, GROSZMANN RJ.Vascular endothelial dysfunction in cirrhosis[J].J Hepatol, 2007, 46 (5) :927-934.

[10]NISHIYAMA SK, ZHAO J, WRAY DW, et al.Vascular function and endothelin-1:tipping the balance between vasodilation and vasoconstriction[J].J Appl Phys, 2017, 122 (2) :354-360.

[11]SIRAGUSA M, FLEMING I.The e NOS signalosome and its link to endothelial dysfunction[J].Pflugers Arch, 2016, 468 (7) :1125-1137.

[12]DU PLESSIS J, VANHEEL H, JANSSEN CE, et al.Activated intestinal macrophages in patients with cirrhosis release NO and IL-6that may disrupt intestinal barrier function[J].J Hepatol, 2013, 58 (6) :1125-1132.

[13]BOLOGNESI M, di PASCOLI M, VERARDO A, et al.Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis[J].World J Gastroenterol, 2014, 20 (10) :2555-2563.

[14]MLLER S, HOBOLTH L, WINKLER C, et al.Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis[J].Gut, 2011, 60 (9) :1254-1259.

[15]MLLER S, HENRIKSEN JH, BENDTSEN F.Extrahepatic complications to cirrhosis and portal hypertension:haemodynamic and homeostatic aspects[J].World J Gastroenterol, 2014, 20 (42) :15499-15517.

[16]MLLER S, BERNARDI M.Interactions of the heart and the liver[J].Eur Heart J, 2013, 34 (36) :2804-2811.

[17]MONTECUCCO F, di MARZO V.At the heart of the matter:the endocannabinoid system in cardiovascular function and dysfunction[J].Trends Pharmacol Sci, 2012, 33 (6) :331-340.

[18]GASKARI SA, LIU H, MOEZI L, et al.Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats[J].Br J Pharmacol, 2005, 146 (3) :315-323.

[19]AL KURY LT, VOITYCHUK OI, ALI RM, et al.Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes[J].Cell Calcium, 2014, 55 (2) :104-118.

[20]ADEBAYO D, MORABITO V, DAVENPORT A, et al.Renal dysfunction in cirrhosis is not just a vasomotor nephropathy[J].Kidney Int, 2015, 87 (3) :509-515.

[21]KRAG A, BENDTSEN F, HENRIKSEN JH, et al.Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J].Gut, 2010, 59 (1) :105-110.

[22]DURAND F, GRAUPERA I, GINS P, et al.Pathogenesis of hepatorenal syndrome:implications for therapy[J].Am J Kidney Dis, 2016, 67 (2) :318-328.

[23]CAVALLIN M, KAMATH PS, MERLI M, et al.Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:a randomized trial[J].Hepatology, 2015, 62 (2) :567-574.

[24]MLLER S, BENDTSEN F.Cirrhotic multiorgan syndrome[J].Dig Dis Sci, 2015, 60 (11) :3209-3225.

[25]KOCH DG, FALLON MB.Hepatopulmonary syndrome[J].Clin Liver Dis, 2014, 18 (2) :407-420.

[26]KOCH DG, BOGATKEVICH G, RAMSHESH V, et al.Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans[J].Dig Dis Sci, 2012, 57 (2) :516-523.

[27]MACHICAO VI, FALLON MB.Hepatopulmonary syndrome[J].Semin Respir Care Med, 2012, 33 (1) :11-16.

[28]ZHANG J, YANG W, HU B, et al.Endothelin-1 activation of the endothelin B receptor modulates pulmonary endothelial CX3CL1 and contributes to pulmonary angiogenesis in experimental hepatopulmonary syndrome[J].Am Pathol, 2014, 184 (6) :1706-1714.

[29]RAEVENS S, GEERTS A, van STEENKISTE C, et al.Hepatopulmonary syndrome and portopulmonary hypertension:recent knowledge in pathogenesis and overview of clinical assessment[J].Liver Int, 2015, 35 (6) :1646-1660.

[30]IVERSEN P, SRENSEN M, BAK LK, et al.Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy[J].Gastroenterol, 2009, 136 (3) :863-871.

[31]DAM G, KEIDING S, MUNK OL, et al.Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake[J].Hepatology, 2013, 57 (1) :258-265.

[32]MOREAU R, JALAN R, GINES P, et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J].Gastroenterol, 2013, 144 (7) :1426-1437.

[33]ARROYO V, MOREAU R, JALAN R, et al.Acute-on-chronic liver failure:a new syndrome that will re-classify cirrhosis[J].J Hepatol, 2015, 62 (1) :131-143.

[34]SARIN SK, KEDARISETTY CK, ABBAS Z.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014[J].Hepatol Int, 2014, 8 (4) :453-471.

[35]MOREAU R.The Pathogenesis of ACLF:The inflammatory response and immune function[J].Semin Liver Dis, 2016, 36 (2) :133-140.

[36]HERNAEZ R, SOLE, MOREAU R, et al.Acute-on-chronic liver failure:an update[J].Gut, 2017, 66 (3) :541-553.

[37]WASMUTH HE, KUNZ D, YAGMUR E, et al.Patients with acute on chronic liver failure display‘sepsis-like’immune paralysis[J].J Hepatol, 2005, 42 (2) :195-201.

[38]BERNSMEIER C, POP OT, SINGANAYAGAM A, et al.Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J].Gastroenterol, 2015, 148 (3) :603-615.

[39]LI H, CHEN HS, NYBERG SL.Extracorporeal liver support and liver transplant for patients with acute-on-chronic liver failure[J].Semin Liver Dis, 2016, 36 (2) :153-160.

[40]BAARES R, NEVENS F, LARSEN FS, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure:the RELIEF trial[J].Hepatology, 2013, 57 (3) :1153-1162.

[41]ZHENG Z, LI X, LI Z, et al.Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure:a meta-analysis and meta-regression[J].Exp Ther Med, 2013, 6 (4) :929-936.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2147) PDF downloads(445)

Research advances in the pathogenesis of multiple organ dysfunction syndrome in patients with liver cirrhosis and related treatment regimens

DOI: 10.3969/j.issn.1001-5256.2017.06.032

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances in the pathogenesis of multiple organ dysfunction syndrome in patients with liver cirrhosis and related treatment regimens

DOI: 10.3969/j.issn.1001-5256.2017.06.032

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content